optic neuritis glp 1 Nerve Stroke and NAION Linked to GLP-1 Medications While GLP-1 drugs have been

A drug can be a clinical miracle, but if it is excluded from the formularies of the Big 3 PBMs, it will be inaccessible to the majority of the insured population, and its sales will fail to meet expectations

The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy, which could be a major boost for Pfizer after it faced several setbacks in developing obesity drugs

Other common side effects include headaches, injection site reactions, and nasopharyngitis, but these do not usually result in discontinuation of the drug [74-77]

Nevertheless, peptide-based obesity treatments are pushing forward